Albert David
- Market cap
- ₹ 431 Cr.
- P/E
- 19.1x
- P/B
- 1.14x
- 52-week range
- 579.9 – 931.85
- ROE
- 0%
- ROCE
- 1%
- Dividend yield
- 0.6%
- Debt / equity
- 0.08
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Albert David Limited is an India-based pharmaceutical company. The Company's principal business is manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs by way of domestic sale or export. Its product categories include formulations and bulk drugs. Its product range includes Placentrex range, Anaflam range and BREAZE range. Its formulations include parenteral, oral/enteral, topical agents and vision care. Its parenteral categories include amino acids infusion, anti-microbial, anti-leishmaniasis (kalazar), haemostat (inj), lvp, neurotropic vitamin and placenta extract. The Company's oral/enteral categories include amino acids oral, anthelmintic, anti-microbial, anti-ulcer ants, anti-vertigo, appetite stimulants, anti-tubercular, expectorant / cough syrup, hematinic, haemostat, hepato protective (ayurveda) and hepato protective (others). Its vision care categories include anti glaucoma, anti-infective and NSAID.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Albert David against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)19.1 against a typical 33.2: cheaper than most peers (1st = cheapest).56th of 220
- Sales growth+42.3% against a typical +15.6% from a year earlier.37th of 197
- Profit growth+300% against a typical +18.9% from a year earlier.14th of 160
- Share price, 3 months+12.5% against a typical −1.8%.52nd of 200
- Size₹ 431.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).104th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety, with caution
Rated A by CARE- CARE expects things to get worse (negative outlook).
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE A | Negative | 2 Jul 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 2 Jul 2026 | Reaffirmed | CARE A | — | CARE | ₹ 62.5 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 6 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 12 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 11 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 12 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 2 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 13 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 93 | 88 | 89 | 89 | 98 | 83 | 75 | 71 | 87 | 90 | 86 | 101 |
| Expenses | 77 | 80 | 79 | 88 | 92 | 82 | 80 | 81 | 85 | 79 | 83 | 91 |
| Operating Profit | 16 | 8 | 10 | 1 | 6 | 1 | −5 | −11 | 3 | 11 | 3 | 11 |
| OPM % | 17% | 9% | 11% | 1% | 6% | 0.8% | −6% | −15% | 2.9% | 12% | 3.2% | 10% |
| Other Income | 12 | 17 | 10 | 23 | 21 | −9 | −5 | 22 | −2 | 12 | −25 | 28 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
| Depreciation | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 |
| Profit before tax | 27 | 23 | 18 | 22 | 25 | −10 | −12 | 8 | −3 | 20 | −25 | 36 |
| Tax % | 24% | 20% | 29% | 15% | 28% | −8% | −13% | 6% | 28% | 23% | −15% | 11% |
| Net Profit | 20 | 19 | 13 | 19 | 18 | −9 | −10 | 8 | −3 | 15 | −21 | 32 |
| EPS in Rs | 35.57 | 32.8 | 22.62 | 33.01 | 31.66 | −16.45 | −18.1 | 13.91 | −5.78 | 26.81 | −37.55 | 56.07 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 0%
- 5 Years
- 6%
- 3 Years
- −1%
- TTM
- 11%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 259%
- 10 Years
- 11%
- 5 Years
- 8%
- 3 Years
- 3%
- TTM
- —
- 10 Years
- 9%
- 5 Years
- 10%
- 3 Years
- 8%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Albert David | ₹ 774.90 | ₹ 431 Cr. | 19.1x | 1.1x | 0% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Arun Kumar Kothari
- Executive Chairman of the Board
- Amit Mahla
- Chief Executive Officer, Additional Whole-Time Director
- Ranadeep Bhattacharya
- Chief Financial Officer
- Lalit Lohia
- Company Secretary and Compliance Officer
Prices are delayed and for information only. Nothing on this page is investment advice.